Last update July 29, 2024

プロカインアミド塩酸塩

Compatible

Safe substance and/or breastfeeding is the best option.

Procainamide is a class Ia antiarrhythmic with properties similar to those of quinidine. It is used to treat life-threatening ventricular arrhythmias. Oral or intramuscular administration in doses every 3, 6 or 12 hours.

Excreted in breast milk in clinically insignificant amount: a single study in one mother. (Pittard 1983)

Expert authors consider that the use of this medication during lactation is probably compatible. (Hale, Tan 2001, Cox 1993)

American Academy of Pediatrics: medication usually compatible with breastfeeding. (AAP 2001)

Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs: compatible with Breastfeeding. (WHO 2002)

 

Alternatives

  • Propranolol (Safe substance and/or breastfeeding is the best option.)
  • Quinidine (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

プロカインアミド塩酸塩 is Procainamide Hydrochloride in Japanese.

Is written in other languages:

プロカインアミド塩酸塩 is also known as

Group

プロカインアミド塩酸塩 belongs to this group or family:

Tradenames

Main tradenames from several countries containing プロカインアミド塩酸塩 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 75 - 95 %
Molecular weight 272 daltons
Protein Binding 16 (15 - 20) %
VD 2 l/Kg
pKa 9.04 -
Tmax 0.75 - 2.5 hours
3 (2.5 - 4.5) hours
M/P ratio 4.3 (1 - 7.3) -
Theoretical Dose 1.3 mg/Kg/d
Relative Dose 3.9 - 5.4 %
Ped.Relat.Dose 2.6 - 8.6 %

References

  1. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from https://www.halesmeds.com Consulted on April 10, 2024 Full text (link to original source)
  2. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Abstract Full text (link to original source) Full text (in our servers)
  3. AAP - American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep;108(3):776-89. Abstract Full text (link to original source) Full text (in our servers)
  4. Tan HL, Lie KI. Treatment of tachyarrhythmias during pregnancy and lactation. Eur Heart J. 2001 Abstract Full text (link to original source) Full text (in our servers)
  5. Cox JL, Gardner MJ. Treatment of cardiac arrhythmias during pregnancy. Prog Cardiovasc Dis. 1993 Sep-Oct;36(2):137-78. Review. No abstract available. Abstract
  6. Pittard WB 3rd, Glazier H. Procainamide excretion in human milk. J Pediatr. 1983 Apr;102(4):631-3. No abstract available. Abstract

Total visits

104

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM